AFFILIATIONS
1 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
2 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
3 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
4 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
5 The Pakistan Kidney and Liver Institute and Research Center, Lahore, Punjab, Pakistan
6 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
7 King Hussien Cancer Center, Amman, Jordan, The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States
8 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
9 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
10 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
ABSTRACT
Background:
Alternative-donor allogeneic hematopoietic cell transplantation (allo-HCT) has expanded access to potentially curative therapy for older adults with hematologic malignancies. Comparative outcomes of haploidentical (haplo) versus mismatched unrelated donor (MMUD) transplantation in patients aged ≥70 years remain incompletely defined. We aimed to compare clinical outcomes of haplo versus MMUD allo-HCT with post-transplant cyclophosphamide (PTCy)-based GVHD prophylaxis in adults aged ≥70 years.
Methods:
In this retrospective study, we aimed to compare clinical outcomes of haploidentical versus mismatched unrelated donor allo-HCT with PTCy-based GVHD prophylaxis in adults aged ≥70 years. We analyzed patients who underwent first allo-HCT with reduced-intensity or non-myeloablative conditioning using the publicly available P-6144 dataset from the Center for International Blood and Marrow Transplant Research (CIBMTR). Baseline characteristics were compared with the Mann-Whitney U test and the chi-square test estimated by Kaplan-Meier methods. Relapse, non-relapse mortality (NRM), grade II–IV and III–IV acute GVHD, and chronic GVHD were analyzed with competing-risk methods. Multivariable Cox and Fine-Gray models adjusted for age, Disease Risk Index, HCT-CI, Karnofsky performance status, conditioning intensity, graft source, and CMV serostatus. Statistical significance was defined as P<0.05.
Results:
A total of 669 patients met inclusion criteria (haplo n=581; MMUD n=88). Baseline characteristics were generally balanced. Haplo recipients were slightly older (median 72 [IQR 71–74] vs 71 [IQR 70–72.5] years; P=0.010) and more often male (71% vs 52%; P<0.001). HLA mismatch degree differed as expected (haplo predominantly 4/8 [74%] or 5/8 [21%]; MMUD predominantly 7/8 [95%]; P<0.001). Disease distribution (AML ~51–54%, MDS/MPN ~35–39%), Disease Risk Index (intermediate ~63–68%), HCT-CI ≥3 (53% vs 60%), Karnofsky performance status ≥90 (46% vs 45%), graft source (PBSC 79% vs 86%), conditioning intensity (RIC/NMA 93–94%), and CMV serostatus were otherwise similar (all P>0.05). Median OS was 24.1 months for haplo and 22.1 months for MMUD recipients. In univariable analyses, donor type was not associated with OS (HR 0.97, 95% CI 0.72–1.31; P=0.86), NRM (sHR 0.76, 95% CI 0.49–1.20; P=0.24), grade II–IV acute GVHD (sHR 0.81, 95% CI 0.50–1.31; P=0.40), grade III–IV acute GVHD (sHR 0.67, 95% CI 0.24–1.85; P=0.44), or chronic GVHD (sHR 0.78, 95% CI 0.50–1.22; P=0.28). Relapse showed a non-significant trend toward higher risk with MMUD (sHR 1.41, 95% CI 0.98–2.04; P=0.067). In multivariable models, results remained consistent. Donor type was not associated with OS (aHR 0.95, 95% CI 0.70–1.29; P=0.74), NRM (aSHR 0.74, 95% CI 0.47–1.16; P=0.19), grade II–IV acute GVHD (aSHR 0.79, 95% CI 0.47–1.32; P=0.36), or chronic GVHD (aSHR 0.76, 95% CI 0.48–1.20; P=0.24). Relapse continued to show a borderline higher risk with MMUD that did not reach statistical significance (aSHR 1.46, 95% CI 0.99–2.15; P=0.054). Grade III–IV acute GVHD events were rare in the MMUD cohort (only 4 events), precluding stable multivariable estimation.
Conclusions:
Among adults aged ≥70 years undergoing reduced-intensity allo-HCT with PTCy, haploidentical and mismatched unrelated donor platforms yielded comparable overall survival, NRM, and GVHD outcomes. A trend toward higher relapse with MMUD that did not reach statistical significance warrants further study. Both donor types appear reasonable options for older transplant candidates.
DISCLOSURES
Muhammad Kashif Amin, MD, MSc, FACP: No relevant conflicts of interest to declare.